Investment Thesis
CARB-X accelerates global antibacterial innovation by funding the development of new antibiotics and other life-saving products to combat drug-resistant bacteria, ensuring these treatments are available worldwide.
Stage Focus
Early development to advanced development (clinical trials)
Preferred startup development maturity for initial funding deployment.
Sectors & Themes
Antibacterial innovation, novel antibiotics, diagnostics, preventatives, and life-saving products against drug-resistant bacteria
Core thematic spaces, technologies, and target market segments of interest.
Check Size Range
N/A
Standard financial allocation per investment round.
Outreach & Dossier Intelligence
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...
Investment Team (10)
B
Beth Amiott
Alliance Director
B
Betsy Wonderly Trainor
Alliance Director
D
Damiano de Felice
Chief of External Affairs
D
Daniel Burgess
Chair of the CARB-X Joint Oversight Board
E
Ed Buurman
Alliance Director
E
Erin Duffy
Chief of Research & Development
K
Kevin Outterson
Executive Director
R
Richard Alm
Interim Chief of Research and Development
T
Trudy Grossman
Alliance Director
V
Vega Masignani
Alliance Director